Year: 2025
Type: article
Abstract: Ozanimod is an oral medication indicated for the treatment of moderately-to-severely active ulcerative colitis (UC) in adults. This review article summarises the latest data on the long-term efficacy and safety of ozanimod in patients with UC, presented at the United European Gastroenterology Week (UEGW) held in Vienna, Austria, between 12th–15th October 2024 and the American College of Gastroenterology’s (ACG) Annual Scientific Meeting held in Philadelphia, Pennsylvania, USA, between 25th–30th October 2024. Updated analyses of the True North study (which met its primary endpoint) and associated ongoing open label extension (OLE) study demonstrated that ozanimod efficacy and generally well tolerated safety profile were durable over 5 years of continuous treatment. In a real-world setting, ozanimod induced a clinical response in both advanced therapy (AT)-naïve and AT-experienced patients, though remission rates were slightly lower in patients with prior exposure to ≥3 ATs. In addition, an evaluation of long-term exposure to ozanimod over 16,000 patient years (PY), in a pooled analysis of clinical studies in moderately-to-severely active UC or relapsing multiple sclerosis (RMS), showed that incidence rates for the most frequent treatment-emergent adverse events (TEAE) and TEAEs of interest were low and were similar across both patient populations. Together, these new data confirm that the ongoing efficacy and safety profile of ozanimod is consistent with previous analyses.
Source: European Medical Journal
Author: Nicola Humphry
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Genetics
Domain: Life Sciences
Open Access status: diamond
Funder: Bristol-Myers Squibb
OpenAlex ID: W4407588359